Register

Basket Updated

0

Items added

View Featured Offers >>
1% for the planet logo

Resources results for "NFkB-p65"

  • Products (37)
  • Resources (54)

NF-κB Signaling

Explore the NFkB pathway and its impact on inflammation and immune responses. Click here to learn more about this signaling pathway.

Virus Detection and Innate Immune Activation

Products and Related Resources for Virus Detection and Innate Immune Activation SARS-CoV-2 Research

PTMScan® Direct Apoptosis & Autophagy

Information and case study data for the PTMScan Direct Apoptosis/Autophagy Service offered by CST.

Resources

Please refer to these links from the Gilmore Lab at Boston University, which list NFkB activators and inhibitors reported in the literature:

Activators: http://www.bu.edu/nf-kb/physiological-mediators/inducers/

Inhibitors: http://www.bu.edu/nf-kb/physiological-mediators/inhibitors/

Cytokines and Inflammation

Products and Related Resources for Cytokines and Inflammation SARS-CoV-2 Research

Matched Antibody Pairs

Find validated CST® matched antibody pairs and streamline the development of your High-Throughput ELISA-Like Immunoassays for screening.

Necrotic Cell Death

Necrosis has been classically defined as an unprogrammed form of cell death that occurs in response to overwhelming chemical or physical insult.

T Cell Receptor Signaling

Expert-reviewed interactive pathway providing a current overview of T Cell Receptor (TCR) Signaling.

Inhibition of Apoptosis

Expert-reviewed interactive pathway providing a current overview of Inhibition of Apoptosis Signaling.

Solutions for Oncology Therapeutics Discovery

Streamline your oncology therapeutic development with CST recombinant monoclonal antibodies, ELISA and cellular assay kits, custom products, and services.

Cell Signaling Technology® Products are Prevalent in CiteAb's Top Antibodies of 2022

Cell Signaling Technology® products are prevalent in CiteAb's Top Antibodies of 2022 with 9 of the top 10 most cited primary antibodies from CST.

Regulation of Apoptosis

Study the intricate machinery of the apoptosis signaling pathway. Click here to learn more and gain insights into programmed cell death mechanisms.

CUT&RUN: A New Way to Analyze Epigenetic Marks and Mechanisms

Learn how CUT&RUN can be performed in as little as 1-2 days using low cell number samples, and how CUT&RUN has been employed to study epigenetic remodeling and alternative splicing directed by the NF-κB pathway downstream of a viral oncoprotein.

Resources

We do not observe any bias toward euchromatin or heterochromatin in our assays. In CUT&RUN, the target-specific antibody recruits the pAG-MNase and directs digestion to chromatin that is directly adjacent to the antibody, whether that be in euchromatin or heterochromatin. In this case, the active tethering of pAG-MNase to the chromatin allows for digestion to occur even in less accessible heterochromatin. Our CUT&RUN Assay Kit #86652 has been shown to work well with antibodies against active, accessible euchromatic histone modifications (see Tri-Methyl-Histone H3 (Lys4) (C42D8) Rabbit mAb #9751) and activating transcription factors (see NF-kB p65 [D14E12] XP® Rabbit mAb #8242…

Exceptional Performance of XP® Monoclonal Antibodies

Case Study 4: Exceptional Performance of XP Monoclonal Antibodies from Cell Signaling Technology.

CUT&RUN Frequently Asked Questions

CUT&RUN Frequently Asked Questions (FAQs) from Cell Signaling Technology, Inc.

Toll-like Receptor Signaling

Expert-reviewed interactive pathway providing a current overview of TLR signaling.

p38 MAPK Signaling

Interactive p38 MAPK pathway. Learn how p38 MAPK is involved in regulation of HSP27, MAPKAPK-2, MAPKAPK-3, & several transcription factors.

Death Receptor Signaling

Expert-reviewed interactive pathway providing a current overview of Death Receptor Signaling.

Overview of the Immune System

The immune system is composed of tissues, cells, and molecules whose primary function is to detect, respond to, and eliminate pathogens and transformed cells.

Mechanisms of Cell Death: Necrosis & Necroptosis

Activated by pro-inflammatory signaling, ischemic injury or viral infection, necroptosis is a programmed regulated form of necrosis requiring RIP3 and MLKL

Rheumatoid Arthritis Pathogenesis Signaling Pathway

Expert-reviewed interactive diagram of Rheumatoid Arthritis Pathogenesis and relevant antibodies for studying targets associated with the autoimmune disease.

Hallmarks of Cancer: Resisting Cell Death

Cancer cells can resist death. They evade apoptosis, the mechanism that programs cell death once cells become damaged. Normally, apoptosis helps keep an organism healthy through growth and development, but cancer cells do not follow this process, no matter how abnormally they grow.

T Cell Basics: What a Disease Researcher Needs to Know

This post explores common T cell types, their roles in modulating immune cell response, and T cell activation via interaction with cell surface receptors.

Immunology: What are toll-like receptors and how do they invoke tumor tolerance?

Understanding how TLR signaling is activated by molecular patterns is relevant not only to their role in combating infection but also in cancer.

Protocol Compatibility Table for Immune Signaling and Phenotyping by Flow Cytometry

Use our protocol compatibility table to understand which immune signaling and phenotyping antibodies will work together in your multicolor flow cytometry experiment.

Novel Therapeutic Approaches for Diffuse Large B-Cell Lymphoma

Lymphoma is a cancer of the lymphatic system, a key part of the body’s immune system. Treatment options & patient prognoses differ based on lymphoma type.

Mechanisms of Cell Death: Pyroptosis

Pyroptosis is a type of programmed necrotic cell death activated by infections from bacteria, viruses, fungi or protozoa in the presence of PAMPs or DAMPs

ChIP Validated Antibodies and Primer Pairs

SimpleChIP Kits and Antibodies validated in-house by our antibody development scientists correlated to positive and negative control primers.

Therapeutic Approaches for the Treatment of Multiple Myeloma

Recent advancements including next-generation proteasome inhibitors, monoclonal bispecific antibodies, antibody-drug conjugates, and CAR-T therapies that have changed the therapeutic landscape for multiple myeloma.